AURA
Price
$5.67
Change
-$0.27 (-4.55%)
Updated
Feb 4, 02:23 PM (EDT)
Capitalization
377.21M
55 days until earnings call
Intraday BUY SELL Signals
NVAX
Price
$8.27
Change
-$0.10 (-1.19%)
Updated
Feb 4, 03:07 PM (EDT)
Capitalization
1.36B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AURA vs NVAX

Header iconAURA vs NVAX Comparison
Open Charts AURA vs NVAXBanner chart's image
Aura Biosciences
Price$5.67
Change-$0.27 (-4.55%)
Volume$100
Capitalization377.21M
Novavax
Price$8.27
Change-$0.10 (-1.19%)
Volume$700
Capitalization1.36B
AURA vs NVAX Comparison Chart in %
View a ticker or compare two or three
VS
AURA vs. NVAX commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a Hold and NVAX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (AURA: $5.94 vs. NVAX: $8.37)
Brand notoriety: AURA: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AURA: 122% vs. NVAX: 81%
Market capitalization -- AURA: $377.21M vs. NVAX: $1.36B
AURA [@Biotechnology] is valued at $377.21M. NVAX’s [@Biotechnology] market capitalization is $1.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AURA’s FA Score shows that 1 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • AURA’s FA Score: 1 green, 4 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, NVAX is a better buy in the long-term than AURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AURA’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).

  • AURA’s TA Score: 5 bullish, 5 bearish.
  • NVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AURA is a better buy in the short-term than NVAX.

Price Growth

AURA (@Biotechnology) experienced а +4.95% price change this week, while NVAX (@Biotechnology) price change was -14.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

AURA is expected to report earnings on Mar 31, 2026.

NVAX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.36B) has a higher market cap than AURA($377M). NVAX YTD gains are higher at: 24.554 vs. AURA (8.991). NVAX has higher annual earnings (EBITDA): 410M vs. AURA (-112.21M). NVAX has more cash in the bank: 763M vs. AURA (162M). AURA has less debt than NVAX: AURA (17.8M) vs NVAX (251M). NVAX has higher revenues than AURA: NVAX (1.07B) vs AURA (0).
AURANVAXAURA / NVAX
Capitalization377M1.36B28%
EBITDA-112.21M410M-27%
Gain YTD8.99124.55437%
P/E RatioN/A4.16-
Revenue01.07B-
Total Cash162M763M21%
Total Debt17.8M251M7%
FUNDAMENTALS RATINGS
NVAX: Fundamental Ratings
NVAX
OUTLOOK RATING
1..100
12
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
10
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AURANVAX
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
AURA
Daily Signal:
Gain/Loss:
NVAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BISAX27.370.16
+0.59%
Brandes International Small Cap Equity A
FELAX125.93N/A
N/A
Fidelity Advisor Semiconductors A
LLEIF1.55N/A
N/A
Lleidanetworks Serveis Telematics S A
WPVIX31.65-0.48
-1.49%
Weitz Multi Cap Equity-Institutional Cl
MFCSF11.92-0.24
-1.97%
Medical Facilities Corp.

AURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AURA has been loosely correlated with NUVL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AURA
1D Price
Change %
AURA100%
+1.02%
NUVL - AURA
50%
Loosely correlated
+2.12%
DSGN - AURA
49%
Loosely correlated
-0.38%
IDYA - AURA
48%
Loosely correlated
+0.50%
XNCR - AURA
47%
Loosely correlated
-0.99%
SLDB - AURA
46%
Loosely correlated
+1.71%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-3.68%
MRNA - NVAX
57%
Loosely correlated
-0.82%
FHTX - NVAX
42%
Loosely correlated
-2.74%
BNTX - NVAX
42%
Loosely correlated
-0.58%
CRSP - NVAX
38%
Loosely correlated
+1.34%
AURA - NVAX
38%
Loosely correlated
+1.02%
More